An observational study in Rheumatoid Arthritis With Adequate Bone Quality, Inflammatory Arthritis and Osteoarthritis, Hip, sponsored by Zimmer Biomet. Active, not recruiting at 8 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Zimmer Biomet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Osteoarthritis, Hip by Zimmer Biomet — 3 open to participants now, 9 under way, none of them phase 3. Osteoarthritis, Hip · Zimmer Biomet.
Among the 28 studies in Osteoarthritis, Hip by Zimmer Biomet, this one is the 4th largest by enrollment of the 16 observational ones that give a count, is one of 3 that started in 2013, is one of 16 observational ones, and was the 11th registered.
642 studies on the registry are indexed under Osteoarthritis, Hip; 121 are open to participants now.
Browse Osteoarthritis, Hip studies →3 of the 28 studies in Osteoarthritis, Hip by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:
Zimmer Biomet · Sites in United States
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18–80
Zimmer Biomet · Sites in United States, Belgium, Italy and 1 more country
Ages 18–80
By country, each count listing its studies:
Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2013.
This study's enrollment of 250 is above the median of 135 across 158 observational studies indexed under Osteoarthritis, Hip.
Median enrollment 239 across the 12 interventional studies, 176 across the 16 observational. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.
1 of the studies in Osteoarthritis, Hip by Zimmer Biomet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Osteoarthritis, Hip by Zimmer Biomet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, prospective, non-controlled post market clinical follow-up study. The objectives of this study are to confirm the safety and performance of the commercially available Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty.
The objectives of this study are to confirm the safety and performance of the Zimmer Maxera Cup mated with either a BIOLOX® delta or BIOLOX® OPTION femoral head when used in primary total hip arthroplasty.
In total 250 patients will be enrolled into the study at up to 10 sites.All potential study subjects will be required to participate in the Informed Consent Process.
642 studies on the registry are indexed under Osteoarthritis, Hip; 121 are open to participants now.
This study's enrollment of 250 is above the median of 135 across 158 observational studies indexed under Osteoarthritis, Hip.
Browse Osteoarthritis, Hip studies →Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.
Compared within Osteoarthritis, Hip, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient qualifies for primary unilateral or simultaneous bilateral total hip arthroplasty (THA) based on physical exam and medical history including at least one of the following:
Exclusion Criteria:
The patient is:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
Implant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method
Time frame: 10 years post-surgery
Pain and functional performance based on the Harris Hip Score
Time frame: 10 years post-surgery
Pain and functional performance based on the UCLA Score
Time frame: 10 years post-surgery
Subject quality-of-life determined by the EQ-5D (EuroQoI) score
Time frame: 10 years post-surgery
X-rays evaluated for radiolucencies, osteolysis, hypertrophy, subsidence, heterotopic ossification, etc
Time frame: 10 years post-surgery
Safety based on eventual complications occurred including dislocations and revisions/removals
Time frame: 10 years post-surgery
Started Jan 2013 (actual). Primary completion is estimated for Jan 2027, 168 months after the start.
Of 81 observational studies under Osteoarthritis, Hip, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 113. This study's planned 168 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.